Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
03/2005
03/23/2005CN1597676A Jujube kernel saponin derivative and its preparation method and use
03/23/2005CN1596979A Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
03/23/2005CN1596944A Medicine for treating senile dementia and application of related Chinese medicinal composition
03/23/2005CN1596942A Medicament for nourishing heart and relieving mental strain and its preparation method
03/23/2005CN1596934A Head ache capsule preparation
03/23/2005CN1596920A Medicinal composition for treating cardiopathy and its preparation method and use
03/23/2005CN1596915A Medicine for drug rehabilitation
03/23/2005CN1596904A Medicine for regulating nerve system, treating epilepsia disease
03/23/2005CN1596903A Bean curd fruit glycocide softcapsule
03/23/2005CN1596889A Vitamin E emulsion and its freeze-dried emulsion compound and preparation method
03/23/2005CN1194092C Medusa cystatin Protease inhibitor gene, and expression and use therof
03/23/2005CN1194090C Growth factor and genetic sequence for encoding same
03/23/2005CN1194086C Preparing method method of neural stem cell preparation,
03/23/2005CN1193981C Method for preparing memantine hydrochloride
03/23/2005CN1193788C Beta 2-adrenergic receptor agonist
03/23/2005CN1193774C Chinese medicine for dropping drug
03/23/2005CN1193769C Health-care food with sobering function
03/23/2005CN1193767C Medicine formed form ganglioside and erigeron breviscapus extract and health-care product and their application
03/23/2005CN1193763C Rhodiola total tanning matter extract and use for preparing medicine for treating senile dementia
03/23/2005CN1193756C SGK2 and SGK3 used as diagnostic and therapeutic targets
03/23/2005CN1193746C Substituted nitrobenzene derimative for medicine and other use
03/22/2005US6870070 Hydrogenation, resoulution, alkylation, bromination, andcarboxamidation
03/22/2005US6870031 Haemopoietin receptor and genetic sequences encoding same
03/22/2005US6870030 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of nervous system and tumor disorders
03/22/2005US6869975 Linked biaryl compounds
03/22/2005US6869973 Nitrosated and nitrosylated taxanes, compositions and methods of use
03/22/2005US6869969 Isoxazole estrogen receptor agonist and antagonist
03/22/2005US6869962 Benzofused heterozryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use
03/22/2005US6869960 Substituted with a quinolin-3-ylmethyl- group, e.g., 2,3-dihydro-1'-((2-oxo-1,2,3,4-tetrahydro-3-quinolinyl)-methyl)spiro(1H -indene-1,4'-piperidine)
03/22/2005US6869955 Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
03/22/2005US6869952 Such as 4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methyl-pyrrolo(2,1-f)(1,2,4)triazin-6-ol; for treament of cancer
03/22/2005US6869946 For therapy of disease or condition in a mammal, wherein the alpha 7 nicotinic acetylcholine receptor is implicated and for therapy of diseases where there is a sensory-gating deficit in a mammal
03/22/2005US6869945 Antihistamines; respiratory system disorders; antiinflammatory agents
03/22/2005US6869941 Combination of drospirenone and an estrogen sulphamate for HRT
03/22/2005US6869622 Extracts of the root of a plant of the family Valerianacae for use in therapy of sleep disorders
03/22/2005US6869610 Pain treatment by peripheral administration of a neurotoxin
03/22/2005US6869600 Combined treatment of multiple sclerosis
03/22/2005CA2330092C Benzimidazole compounds as orl1-receptor agonists
03/22/2005CA2257772C Bicyclic¬3.1.0|hexanes and related compounds
03/22/2005CA2178219C Substituted morpholine derivatives and their use as therapeutic agents
03/17/2005WO2005023815A2 Neuroprotective bicyclic compounds and methods for their use
03/17/2005WO2005023807A2 4 - heterobicyclyamino - substituted quinazolines and analogues therof as capsaicin - antagonists
03/17/2005WO2005023802A1 Pyridinylmorpholine derivatives
03/17/2005WO2005023782A1 Substituted fused pyrimidine-4(3h)-one compound
03/17/2005WO2005023763A1 Process for the preparation of pure levetiracetam
03/17/2005WO2005023753A1 A method of preparing memantine hydrochloride
03/17/2005WO2005023741A2 Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives
03/17/2005WO2005023286A1 Medical agent for prevention and/or treatment of alzheimer disease
03/17/2005WO2005023285A2 Agent and method for the treatment and prevention of tse and method for the production of said agent
03/17/2005WO2005023279A1 Anti-stress composition and inhaler therefor
03/17/2005WO2005023269A1 Medicament compositions comprising a heterocyclic compound and an anticholinergic
03/17/2005WO2005023266A1 The combination of a serotonin reuptake inhibitor and amoxapine
03/17/2005WO2005023265A1 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
03/17/2005WO2005023261A1 1-benzoyl-piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
03/17/2005WO2005023260A1 1- (2-amino-benzol) -piperazine derivatives as glycine uptake inhibitors for the treatment of psychoses
03/17/2005WO2005023256A1 Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
03/17/2005WO2005023250A1 Use of telmisartan for the prevention of vascular headache
03/17/2005WO2005023243A1 The combination of a serotonin reuptake inhibitor and loxapine
03/17/2005WO2005023238A1 Erg channel openers for the treatment of hyperexcitability-related neuronal diseases
03/17/2005WO2005023231A1 Polypyrimidine tract binding protein promotes insulin secretory granule biogenesis
03/17/2005WO2005023230A1 Composition containing nanoparticles containing water-soluble basic drug encapsulated therein
03/17/2005WO2005023198A2 Modafinil compositions
03/17/2005WO2005000820A3 4-cyanopyrazole-3-carboxamide derivatives preparation and application thereof as cb1 cannabinoid antagonists
03/17/2005WO2005000817A3 Diphenylpyridine derivatives, preparation and therapeutic application thereof
03/17/2005WO2004106275A3 Compounds useful in the therapy of alzheimer’s disease and formulations containing them
03/17/2005WO2004099395A3 A method for the generation of neural progenitor cells
03/17/2005WO2004098622A3 Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic-pituitary-adrenal axis over-activity
03/17/2005WO2003045918A8 Piperidine-based mch antagonists for treatment of obesity and cns disorders
03/17/2005WO2003037887A8 Therapeutic isoquinoline compounds
03/17/2005WO2002072571A8 Pyridinyl pyrazoles useful for the treatment of copd
03/17/2005US20050059826 Agonists, antagonists or inverse agonists for brain receptors; anxiolytics, antidepressants; nervous system, sleep and psychological disorders; Down syndrome, cognition activators
03/17/2005US20050059735 Cyclic amino acid derivatives useful as pharmaceutical agents
03/17/2005US20050059729 Substituted cyclic compounds
03/17/2005US20050059726 For treating thrombosis and factor xa-related cardiovascular and neurodegenerative diseases; 6-Chloro-N-{(3S)-1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl}naphthalene-2-sulfonamide for example
03/17/2005US20050059725 Treating schizophrenia or Parkinson's disease with thiolutin dioxide
03/17/2005US20050059715 Treatment of pain, particularly neuropathic pain; with serotonin re-uptake inhibitor (gabapentin), serotonin re-uptake inhibitor (sertraline, fluoxetine), noradrenaline re-uptake inhibitor (reboxetine) or serotonin-noradrenaline re-uptake inhibitor (venlafaxine)
03/17/2005US20050059714 2-Cyclopropyl-4-(5-fluoro-2-methoxyphenyl)-4-methyl-1-(1H-pyrrolo[2,3-c]pyridin-2-yl)pentan-2-ol; treating diseases of inflammatory, allergic, or proliferative condition; type II diabetes, obesity, cardiovascular diseases, hypertension, arteriosclerosis, neurological diseases, adrenal and pituitary tumor
03/17/2005US20050059700 Reacting compunds such as 6-methyl-12-oxa-tricyclo[8.2.1.0]trideca-2,4,6-trien-11-ol with compounds such as 4-(2,6-dichloro-phenyl)-piperidine to produce (+-)-cis-1-methyl-7-[[4-(2,6-dichloro-phenyl)piperidin-1-yl)]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol
03/17/2005US20050059698 Cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration disease, behavioral or psychological disorders; N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-2,3-dihydro-1,4-benzodioxine-6-carboxamide L-malate; including antipsychotic drugs
03/17/2005US20050059688 administering nontoxic, preferential and potent c-kit ligand inhibitors such as imatinib, to humans for treatment of inflammatory diseases such as rheumatoid arthritis
03/17/2005US20050059686 Pyrrolopyrimidines as phosphodiesterase vII inhibitors
03/17/2005US20050059683 A1 adenosine receptor antagonists
03/17/2005US20050059680 Crystalline ziprasidone HCI and processes for preparation thereof
03/17/2005US20050059675 Antidepressants; N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]-1,2-dihydro-3H-benzo[e]indole-3-carboxamide; antagonist of adrenergic receptor, serotonin receptor; anxiety, schizophrenia, Parkinson's disease, cognitive disorders, schizophrenia
03/17/2005US20050059673 serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer
03/17/2005US20050059668 Substituted acylpiperazine derivatives
03/17/2005US20050059666 CCR5 antagonists useful for treating AIDS
03/17/2005US20050059665 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
03/17/2005US20050059657 Aminoisoxazole derivatives active as kinase inhibitors
03/17/2005US20050059654 Method for treatment of depression and anxiety disorders by combination therapy
03/17/2005US20050059652 Open chain prolyl urea-related modulators of androgen receptor function
03/17/2005US20050059634 Compositions, and methods that inhibit the formation and/or activity of Alzheimer's disease diffusible ligands(ADDLs), and, consequently, are useful in the treatment of Alzheimer's disease and other diseases and conditions associated with ADDLs
03/17/2005US20050059627 Administering antisense oligonucleotides against the mRNA of corticotropin releasing factor subtype-2 (CRF2) receptor; treating anxiety, obsessive-compulsive disorder, panic disorders, post-traumatic stress, phobias and depression
03/17/2005US20050059616 administering flavonoids and optionally vitamin E or excipients for the prophylaxis of bone or cardiovascular disorders, headaches, hypertension, cancers, leukemia, arteriosclerosis, Alzheimer's disease, inflammatory diseases, rheumatic diseases, acne, alopecia or psoriasis
03/17/2005US20050059608 Pharmaceutical compounds
03/17/2005US20050059594 Administering macrophage derived factor; oncomodulin
03/17/2005US20050059586 For increasing expression of human presenilin; for treatment of neurodegenerative diseases, Alzheimer's disease; drug screening
03/17/2005US20050059577 Glycosylphosphatidylinositol containing polypeptides
03/17/2005US20050059093 Method for detecting modulators of Notch signalling
03/17/2005US20050059092 Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
1 ... 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 ... 1833